Valuation: Alector, Inc.

Market Cap 168M 146M 136M 125M 235M 16B 239M 1.6B 628M 7.97B 630M 616M 26.72B P/E 2026 *
-1.76x
P/E 2027 * -2.35x
Enterprise Value -79.49M -69.1M -64.31M -59.05M -112M -7.59B -113M -758M -298M -3.78B -299M -292M -12.67B EV / Sales 2026 *
-11.6x
EV / Sales 2027 * -6.94x
Free-Float
86.82%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Alector, Inc.

1 day-6.79%
1 week+2.03%
1 month-24.88%
3 months-36.29%
6 months-20.11%
Current year-3.21%
1 week 1.47
Extreme 1.47
1.67
1 month 1.37
Extreme 1.37
2.14
Current year 1.37
Extreme 1.37
2.74
1 year 1.09
Extreme 1.09
3.4
3 years 0.87
Extreme 0.87
9.06
5 years 0.87
Extreme 0.87
29.3
10 years 0.87
Extreme 0.87
43.32
Manager TitleAgeSince
Chief Executive Officer 71 01/05/2013
Director of Finance/CFO 52 20/06/2025
Chief Tech/Sci/R&D Officer - 01/01/2017
Director TitleAgeSince
Director/Board Member 71 01/05/2013
Director/Board Member 72 01/10/2018
Chairman 77 13/06/2023
Date Insider Type Main position Quantity % Market Cap.
9/7/26 Free

Controller/Auditor

20,000 0.0180%
26/2/26 Sell

Controller/Auditor

4,079 0.0037%
5/12/25 Sell

Controller/Auditor

4,753 0.0044%
Change 5-day change 1-year change 3-year change Capi.($)
-6.79%+2.03%+1.34%-77.99% 168M
+2.35%+2.74%+33.41%+79.20% 56.54B
-0.21%-7.38%+25.34%+63.02% 53.6B
-2.44%+1.40%-15.74%-16.80% 22.91B
-2.85%-7.78%-8.09%+346.36% 21.37B
+2.49%-0.92%+20.31%-12.15% 20.27B
+0.79%-1.06%+29.29%-33.32% 17.56B
+0.58%-5.88%+16.30%+540.37% 14.75B
-5.25%-4.23%+46.41%+169.05% 13.33B
+3.41%-6.61%+163.08%+280.43% 13.53B
Average -0.79%-3.21%+31.16%+133.82% 23.4B
Weighted average by Cap. +0.23%-2.96%+28.65%+119.84%

Financials

2026 *2027 *
Net sales 6.86M 5.96M 5.55M 5.09M 9.62M 655M 9.77M 65.4M 25.67M 326M 25.75M 25.19M 1.09B 22.88M 19.89M 18.51M 17M 32.1M 2.18B 32.6M 218M 85.65M 1.09B 85.93M 84.05M 3.65B
Net income -94.11M -81.81M -76.15M -69.91M -132M -8.98B -134M -898M -352M -4.47B -353M -346M -15B -96.62M -83.99M -78.17M -71.77M -136M -9.22B -138M -921M -362M -4.59B -363M -355M -15.4B
Net Debt -247M -215M -200M -184M -347M -23.59B -352M -2.36B -925M -11.74B -928M -908M -39.38B -326M -284M -264M -242M -458M -31.16B -465M -3.11B -1.22B -15.51B -1.23B -1.2B -52.01B
Logo Alector, Inc.
Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. It also develops alector brain carrier (ABC), a proprietary blood-brain barrier platform, which is applied to its next-generation product candidates and research pipeline. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration. Its clinical development portfolio includes latozinemab (AL001) and AL101/GSK4527226, while its preclinical and research pipeline candidates include ADP037-ABC, ADP050-ABC, ADP056, and ADP063-ABC/ADP064-ABC. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients. The AL101/GSK4527226, is a human recombinant monoclonal antibody designed to elevate PGRN levels in the brain.
Employees
103
Date Price Change Volume
31/07/26 US$1.510 -6.79% 548,294
30/07/26 US$1.620 +6.58% 453,153
29/07/26 US$1.520 -.--% 307,858
28/07/26 US$1.520 +0.66% 342,803
27/07/26 US$1.510 +2.03% 229,001
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
1.510USD
Average target price
3.100USD
Spread / Average Target
+105.30%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALEC Stock